<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 51-year-old woman with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> developed HHV-6 <z:hpo ids='HP_0002383'>encephalitis</z:hpo> on day 34 after unrelated bone marrow transplantation </plain></SENT>
<SENT sid="1" pm="."><plain>Although prompt treatment with foscarnet stabilized <z:hpo ids='HP_0002383'>encephalitis</z:hpo> and there were no serious neurological sequelae, the patient developed both <z:hpo ids='HP_0002902'>hyponatremia</z:hpo> and <z:mp ids='MP_0006316'>natriuresis</z:mp> 11 days after intravenous administration of foscarnet </plain></SENT>
<SENT sid="2" pm="."><plain>Subsequent investigation demonstrated <z:hpo ids='HP_0002902'>hyponatremia</z:hpo> due to <z:hpo ids='HP_0000127'>salt-wasting</z:hpo> <z:hpo ids='HP_0000112'>nephropathy</z:hpo> induced by foscarnet </plain></SENT>
<SENT sid="3" pm="."><plain>Discontinuation of foscarnet and fluid replacement therapy with adequate <z:chebi fb="40" ids="26710">sodium chloride</z:chebi> (<z:chebi fb="1" ids="26710">NaCl</z:chebi>) resulted in a gradual resolution of <z:hpo ids='HP_0002902'>hyponatremia</z:hpo> and <z:mp ids='MP_0006316'>natriuresis</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>Currently, 8 months after these clinical events, the patient is under outpatient treatment for persistent <z:hpo ids='HP_0000112'>nephropathy</z:hpo> that requires small amounts of oral <z:chebi fb="1" ids="26710">NaCl</z:chebi> supplement, but she is otherwise in good clinical condition </plain></SENT>
</text></document>